RICHMOND, Va., April 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq:INDV), a leader in the treatment of opioid use disorder (OUD), will present one new scientific poster and collaborated with VA Tech on a second poster which will be presented at the American Society of Addiction Medicine (ASAM) Annual Conference, held April 23-26, 2026, in San Diego, California. The data add to the growing body of evidence evaluating extended-release buprenorphine, a monthly injectable commercially available as SUBLOCADE®, in supporting meaningful outcomes for people living with OUD, including overdose-related outcomes and broader indicators associated with recovery.
Read more at globenewswire.comThis article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
/Apple%20Inc%20logo%20on%20Apple%20store-by%20PhillDanze%20via%20iStock.jpg)
/Microsoft%20sign%20at%20the%20headquarters%20by%20VDB%20Photos%20via%20Shutterstock.jpg)
